Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Angelika Walzl
Observed names:
A. Walzl,
Walzl, Angelika
Institution:
Medical University of Vienna
Observed institution:
Medical University of Vienna
OpenAlex ID:
A5113671972
In vitro cell migration and invasion assays
2012
·
Nina Kramer
, Angelika Walzl
, et al.
·
Mutation Research/Reviews in Mutation Research
·
1,335
Modeling human carcinomas: Physiologically relevant 3D models to improve anti-cancer drug development
2014
·
Christine Unger
, Nina Kramer
, et al.
·
Advanced Drug Delivery Reviews
·
173
The Resazurin Reduction Assay Can Distinguish Cytotoxic from Cytostatic Compounds in Spheroid Screening Assays
2014
·
Angelika Walzl
, Christine Unger
, et al.
·
SLAS DISCOVERY
·
116
PDF
Loss of miR-200 family in 5-fluorouracil resistant colon cancer drives lymphendothelial invasiveness in vitro
2015
·
D. Senfter
, S. Holzner
, et al.
·
Human Molecular Genetics
·
84
Increased complexity in carcinomas: Analyzing and modeling the interaction of human cancer cells with their microenvironment
2015
·
Mira Stadler
, Stefanie Walter
, et al.
·
Seminars in Cancer Biology
·
82
Organotypic spheroid cultures to study tumor–stroma interaction during cancer development
2011
·
Helmut Dolznig
, Angelika Walzl
, et al.
·
Drug Discovery Today Disease Models
·
33
Preclinical Cancer Models with the Potential to Predict Clinical Response
2016
·
Martin Scherzer
, Nina Kramer
, et al.
·
Elsevier eBooks
·
1
Der Einfluss der neuen Konsolidierungsstandards nach IFRS auf Konzernabschlüsse am Beispiel der Konzernabschlüsse der Prime Market Unternehmen der Wiener Börse AG / Angelika Walzl
2015
·
Angelika Walzl
Show more works
View as search
Works count:
11
Citation count:
1,836
H-index:
7
I10-index:
7
Year
Topic
Type